could influence the cost and quality of life of patients. To assess the cost-effectiveness of adding a PPI compared to no PPI co-treatment in older patients LDASA. Methods: A cost-effectiveness study was conducted with a Markov model for PPI co-medication (intervention) compared to no PPI co-medication (usual care) in LDASA users. The base case analysis was performed for patients of 70 years old. The models addressed chronic LDASA use of five years. Incremental cost-utility ratio's (ICURs), expressed as costs per QALY gained, were calculated for different age categories (60 up to 80 years) accounting for different risk rates for side effects from LDASA or PPI use. These side effects included gastrointestinal bleeding, dyspepsia, pneumonia and hip fractures. Finally, a budget impact analysis was performed to assess the health care expenditures to add PPIs in all current patients using LDASA above the age of 60 years in the Netherlands. Results: Adding a PPI to LDASA, compared to not adding a PPI, resulted in incremental costs of € 71,84 and incremental effects of 0,006 QALY's and an ICUR of € 11,491.53/QALY gained for the base case analysis. The ICUR for 60-and 80-year old patients was € 11,491.53/QALY and € 53,860.85/QALY, respectively. The total budget impact of adding a PPI to current LDASA users (≥ 60 years) was € 174,475,296. ConClusions: Adding a PPI to LDASA users may be a cost-effective approach in patients from 60 up to 80 years old. However, with increasing age the costs became higher and the effects lower, due to higher risks of the different side effects.
objeCtives: The objective of this study was to analyze the cost-effectiveness of biologics compared to conventional disease-modifying antirheumatic drugs (cDMARDs) for the treatment of rheumatoid arthritis (RA) using real world data from Finnish national registers. Methods: RA patients starting their first biologics 2007 -2011 and comparator patients using cDMARDs during the same time period were obtained from the National register of biologic treatments in Finland (ROB-FIN) and from the Central Finland Central Hospital (CFCH) patient records. Medication changes were allowed and patients were followed up to two years. Propensity score matching was applied to adjust difference between biologics and cDMARD users. Effectiveness in quality adjusted life years (QALY) was based on ROB-FIN and CFCH patient records while the direct costs of medication and health care utilization were obtained from relevant Finnish national registers. Mean costs and effectiveness as well as 95% confidence intervals were calculated using bootstrap resampling approach. Both the costs and effectiveness were discounted at 3%. Results: Of 1487 patients RA patients meeting study inclusion criteria, 608 biologic users and 300 cDMARD users were included in analyses after propensity score matching. Mean follow up times were 463 and 538 days for biologic users and cDMARD users, respectively. Mean costs for biologics and cDMARDs were 57,900 € (CI 95% 54,800 -60,900 € ) and 21,900 € (CI 95% 17,300 -26,500 € ), while mean effectiveness was 1.2064 (CI 95% 1.1756 -1.2373) and 1.2066 QALYs (CI 95% 1.1751 -1.2381), respectively. ConClusions: The high cost of biologics and the small, non-significant difference in effectiveness for the advantage of cDMARDs resulted in cDMARDs being dominant treatment. However, regardless the propensity score matching, latent confounders may introduce bias to the results.
PMS84 CoMParativE EffECtivEnESS and CoSt-EffECtivEnESS of gEnEriC alEndronatE, riSEndronatE, dEnoSuMaB and ZolEndroniC aCid for SECondary PrEvEntion of fragility fraCturES -PErliMinay rESultS
Hagen G Norwegian University of Science and Technology, Trondheim, Norway objeCtives: To evaluate the relative health gains and costs of secondary prevention of fractures with generic alendronate, risedronate, denosumab and zoledronic acid. Methods: We evaluated the cost-effectiveness based on a previously developed decision analytic fracture model. The model synthesizes available data on the epidemiology of fractures and related mortality, need for long-term care and home based assistance. The model is set up as an individual level Markov model and outputs include number of quality adjusted life years (QALYs) and costs. Effectiveness data were gathered from a recent systematic review and costs were collected from publicly available sources. We preformed analyses for women 85 years old with a previous hip fracture. In this first preliminary analysis, we assumed full compliance and lifelong treatment. Results: Zoledronic acid was the most effective alternative, followed by denosumab, risedronate, generic alendronate and no treatment, yielding respectively 4. 7661, 4.7640, 4.6715, 4.1581 and 3.8915 QALYs. In terms of costs, generic alendronate was the best options, being less costly than no secondary prevention. In terms of cost-effectiveness, no treatment, denosumab and risedronate were excluded based on dominance, seeing that alendronate was more effective and less costly than no treatment, and zoledronic acid was more effective and less costly than both denosumab and risedronate. Compared to alendronate, zoledronic acid yields an incremental cost-effectiveness ratio of $48,832 per QALY. ConClusions: All options are effective compared to no treatment. In terms of comparative effectiveness and cost-effectiveness, our analysis indicates that zoledronic acid is the optimal strategy for secondary prevention, assuming a cost-effectiveness threshold of $50,000 per QALY gained. Bootstrap analyses with 1000 replications were used. Results: 180 patients were included; 121 were allocated to the dose optimisation strategy, 59 to control. The dose optimisation strategy resulted in mean cost savings of -€ 12,280 (95 percentile -€ 10,502; -€ 14,104) per patient. There is a 84% chance that the dose optimisation strategy results in QALY loss with a mean loss of -0.02 (-0.07; 0.02). When using a willingness to pay (WTP) level of € 80,000 per QALY, the mean iNMB is € 10,467 (€ 6,553; € 14,037) per patient per 18 months. Sensitivity analyses using prices -30% and -50% still resulted in a cost effective strategy. ConClusions: Disease activity guided dose optimisation of TNFi results in considerable cost savings with no relevant loss of quality of life. When the minimal QALY loss is compensated with the upper limit of what society is willing to pay in Netherlands, the net savings are still high, even when future price drops are taken into account. Despite adding a few more QALYs, all ICERs fell well above the 2014 NICE threshold for cost-effectiveness (24,800€ ). Overall, the model was sensitive to changes in drug prices. Starting with UST potentially saves 41.7€ million over starting with ADA and 318€ million over starting with INF in the 17,000 patients eligible for biologicals. ConClusions: In Russia, the cost-effective approach for patients with moderate-to-severe PsA that failed DMARDs is to initiate biologic therapy with UST, use ADA as second line and INF as third line.
PMS85 tElErEhaBilitation aftEr total KnEE rEPlaCEMEnt: PrEliMinary CoSt-utility analySiS of an innovativE dEviCE

PMS80 EConoMiC analySiS of uStEKinuMaB for PSoriatiC arthritiS in ruSSia
PMS81 toCiliZuMaB in MEthotrExatE-naïvE rhEuMatoid arthritiS -a CoStutility ModEl for SlovaKia
Chang S 1 , Sawyer L 1 , Dejonckheere F 2 , Grichova L 3 , Diamantopoulos A 1 1 Symmetron Limited, Elstree, UK, 2 F. Basel, Switzerland, 3 Roche Slovensko, s.r.o., Bratislava, Slovak Republic objeCtives: To assess the cost-utility of Tocilizumab (TCZ) in the treatment of methotrexate (MTX)-naïve adults with active rheumatoid arthritis (RA) in Slovakia. Methods: A decision tree model was developed to reflect the early management of MTX-naïve adult RA patients in Slovakia. Efficacy, DAS28 remission, for each treatment in the model was derived from a network meta-analysis (NMA) of randomised controlled trials (RCTs) [Sawyer et al. 2015] . Benefits were measured in Quality Adjusted Life years (QALYs) derived by mapping DAS28 scores onto EQ-5D utility weights. The analysis was conducted from the third-party payer perspective, and included direct medical costs (drugs, administration, monitoring). The time horizon is one year, in line with the maximum follow-up period from RCTs. Incremental costs and QALYs associated with TCZ±MTX were compared to anti-tumour necrosis factors (TNFs), including adalimumab (ADA), etanercept (ETN) and infliximab (IFX), within their licensed indications. Each treatment was also compared to MTX alone. Variables related to efficacy, cost and utility were tested in the sensitivity analysis. Results: TCZ±MTX had a lower incremental cost-effectiveness ratio (ICER) than other TNFs ±MTX when compared to MTX alone in base case. When compared head-to-head with TNFs, TCZ was cost-effective, with ICERs range from € 6,500 to € 16,000 per QALY gained in monotherapy and from € 10,000 to € 24,000 per QALY gained in combination therapy. Furthermore, TCZ+MTX dominated IFX+MTX. The full incremental analysis showed that TCZ±MTX was the next most cost-effective strategy after MTX. Results of the sensitivity analysis showed the efficacy variables and the assumption on the utility mapping formula have an impact on the ICERs. ConClusions: The results suggest TCZ is a cost-effective alternative to the approved and reimbursed TNFs, used either as monotherapy or in combination with MTX in the treatment of MTX-naïve adult RA patients in Slovakia.
PMS82
CoSt-EffECtivEnESS of Proton PuMP inhiBitor initiation aiMEd to PrEvEnt uPPEr gaStrointEStinal toxiCity in PatiEntS uSing low-doSE aCEtylSaliCyliC aCid
Sluiter R 1 , Chau SH 2 , Kievit W 1 , Teichert M 1 , Hugtenburg J 2 1 Radboudumc, Nijmegen, The Netherlands, 2 VU university medical center, Amsterdam, The Netherlands objeCtives: Proton pump inhibitors (PPI) are not always added to the treatment of low dose acetylsalicylic acid (LDASA), but is proven to be effective in preventing upper gastrointestinal toxicity. However, PPI's may also have additional side effects that
